Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas
When using post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis for lymphoma patients, it is currently unknown whether a matched unrelated donor (MUD) or a haploidentical related donor is preferable if both are available. In this study we wanted to test whether u...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
28 February 2023
|
| In: |
Transplantation and cellular therapy
Year: 2023, Jahrgang: 29, Heft: 3, Pages: 184.e1-184.e9 |
| ISSN: | 2666-6367 |
| DOI: | 10.1016/j.jtct.2022.11.028 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtct.2022.11.028 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2666636722018012 
|
| Verfasserangaben: | Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Hervé Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gülbas, Jose Diez-Martin, Steven G. E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1852358416 | ||
| 003 | DE-627 | ||
| 005 | 20240328080902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230711s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtct.2022.11.028 |2 doi | |
| 035 | |a (DE-627)1852358416 | ||
| 035 | |a (DE-599)KXP1852358416 | ||
| 035 | |a (OCoLC)1425215135 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mussetti, Alberto |e VerfasserIn |0 (DE-588)129573477X |0 (DE-627)1852358947 |4 aut | |
| 245 | 1 | 0 | |a Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas |c Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Hervé Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gülbas, Jose Diez-Martin, Steven G. E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda |
| 264 | 1 | |c 28 February 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar 25. Dezember 2022, Artikelversion 28. Februar 2023 | ||
| 500 | |a Gesehen am 11.07.2023 | ||
| 520 | |a When using post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis for lymphoma patients, it is currently unknown whether a matched unrelated donor (MUD) or a haploidentical related donor is preferable if both are available. In this study we wanted to test whether using a haploidentical donor has the same results of a MUD. A total of 2140 adults (34% Center for International Blood and Marrow Transplant Research, 66% European Society for Blood and Marrow Transplantation registry) aged ≥18 years who received their first haploidentical hematopoietic cell transplantation (haplo-HCT) or MUD-HCT (8/8 match at HLA-loci A, B, C, and DRB1) for lymphoma using PTCy-based GVHD prophylaxis from 2010 to 2019 were retrospectively analyzed. The majority of both MUD and haploidentical HCTs received reduced intensity/nonmyeloablative conditioning (74% and 77%, respectively) and used a peripheral blood stem cell graft (91% and 60%, respectively) and a 3-drug GVHD prophylaxis (PTCy + calcineurin inhibitor + MMF in 54% and 90%, respectively). Haploidentical HCT has less favorable results versus MUD cohort in terms of overall mortality (hazard ratio [HR= = 1.69; 95% confidence interval [CI], 1.30-2.27; P < .001), progression-free survival (HR=1.39; 95% CI, 1.10-1.79; P = .008), nonrelapse mortality (HR = 1.93; 95% CI, 1.21-3.07; P = .006), platelet engraftment (HR = 0.69; 95% CI, 0.59-0.80; P < .001), acute grade 2-4 GVHD incidence (HR = 1.65; 95% CI, 1.28-2.14; P < .001), and chronic GVHD (HR = 1.79; 95% CI, 1.30-2.48, P < .001). No significant differences were observed in terms of relapse and neutrophil engraftment. Adjusting for propensity score yielded similar results. Whenever MUD is available in a timely manner, it should be preferred over a haploidentical donor when using PTCy-based GVHD prophylaxis for patients with lymphoma. | ||
| 650 | 4 | |a Haploidentical donor | |
| 650 | 4 | |a Lymphoma | |
| 650 | 4 | |a Matched unrelated donor | |
| 650 | 4 | |a Post-transplant cyclophosphamide | |
| 700 | 1 | |a Kanate, Abraham S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Tao |e VerfasserIn |4 aut | |
| 700 | 1 | |a He, Meilun |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hamadani, Mehdi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Finel, Hervé |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boumendil, Ariane |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glass, Bertram |e VerfasserIn |4 aut | |
| 700 | 1 | |a Castagna, Luca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dominietto, Alida |e VerfasserIn |4 aut | |
| 700 | 1 | |a McGuirk, Joseph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blaise, Didier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gülbas, Zafer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Diez-Martin, Jose |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marsh, Steven G. E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paczesny, Sophie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gadalla, Shahinaz M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Zhang, Mei-Jie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Spellman, Stephen R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lee, Stephanie J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bolon, Yung-Tsi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sureda, Anna |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation and cellular therapy |d [Amsterdam] : Elsevier B. V., 2021 |g 29(2023), 3 vom: Feb., Seite 184.e1-184.e9 |h Online-Ressource |w (DE-627)1750919230 |w (DE-600)3056525-X |x 2666-6367 |7 nnas |a Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:3 |g month:02 |g pages:184.e1-184.e9 |g extent:9 |a Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jtct.2022.11.028 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2666636722018012 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230711 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 18 | ||
| 999 | |a KXP-PPN1852358416 |e 4352118486 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Hervé Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gülbas, Jose Diez-Martin, Steven G. E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda"]},"person":[{"family":"Mussetti","display":"Mussetti, Alberto","given":"Alberto","role":"aut"},{"family":"Kanate","display":"Kanate, Abraham S.","role":"aut","given":"Abraham S."},{"given":"Tao","role":"aut","display":"Wang, Tao","family":"Wang"},{"family":"He","role":"aut","given":"Meilun","display":"He, Meilun"},{"display":"Hamadani, Mehdi","given":"Mehdi","role":"aut","family":"Hamadani"},{"display":"Finel, Hervé","role":"aut","given":"Hervé","family":"Finel"},{"role":"aut","given":"Ariane","display":"Boumendil, Ariane","family":"Boumendil"},{"family":"Glass","role":"aut","given":"Bertram","display":"Glass, Bertram"},{"family":"Castagna","given":"Luca","role":"aut","display":"Castagna, Luca"},{"given":"Alida","role":"aut","display":"Dominietto, Alida","family":"Dominietto"},{"given":"Joseph","role":"aut","display":"McGuirk, Joseph","family":"McGuirk"},{"given":"Didier","role":"aut","display":"Blaise, Didier","family":"Blaise"},{"family":"Gülbas","display":"Gülbas, Zafer","role":"aut","given":"Zafer"},{"family":"Diez-Martin","display":"Diez-Martin, Jose","role":"aut","given":"Jose"},{"given":"Steven G. E.","role":"aut","display":"Marsh, Steven G. E.","family":"Marsh"},{"display":"Paczesny, Sophie","role":"aut","given":"Sophie","family":"Paczesny"},{"display":"Gadalla, Shahinaz M.","role":"aut","given":"Shahinaz M.","family":"Gadalla"},{"display":"Dreger, Peter","given":"Peter","role":"aut","family":"Dreger"},{"family":"Zhang","display":"Zhang, Mei-Jie","given":"Mei-Jie","role":"aut"},{"family":"Spellman","display":"Spellman, Stephen R.","role":"aut","given":"Stephen R."},{"role":"aut","given":"Stephanie J.","display":"Lee, Stephanie J.","family":"Lee"},{"family":"Bolon","given":"Yung-Tsi","role":"aut","display":"Bolon, Yung-Tsi"},{"family":"Sureda","given":"Anna","role":"aut","display":"Sureda, Anna"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"28 February 2023","dateIssuedKey":"2023"}],"recId":"1852358416","id":{"eki":["1852358416"],"doi":["10.1016/j.jtct.2022.11.028"]},"physDesc":[{"extent":"9 S."}],"note":["Online verfügbar 25. Dezember 2022, Artikelversion 28. Februar 2023","Gesehen am 11.07.2023"],"relHost":[{"language":["eng"],"part":{"volume":"29","year":"2023","text":"29(2023), 3 vom: Feb., Seite 184.e1-184.e9","extent":"9","pages":"184.e1-184.e9","issue":"3"},"title":[{"title_sort":"Transplantation and cellular therapy","title":"Transplantation and cellular therapy"}],"pubHistory":["Volume 27, issue 1 (January 2021)-"],"note":["Gesehen am 10.03.21"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomasTransplantation and cellular therapy","id":{"zdb":["3056525-X"],"issn":["2666-6367"],"eki":["1750919230"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"TCT"}],"origin":[{"publisherPlace":"[Amsterdam]","dateIssuedKey":"2021","publisher":"Elsevier B. V.","dateIssuedDisp":"2021-"}],"recId":"1750919230"}],"title":[{"title_sort":"Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas","title":"Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas"}],"language":["eng"]} | ||
| SRT | |a MUSSETTIALHAPLOIDENT2820 | ||